There was a trend toward improved OS but did not reach statistical significance. 15 The more recent 2008 meta-analysis showed significant benefit in OS (odds ratio: 0.56; 95% confidence interval [CI]: 0.36–0.85) with doxorubicin–ifosfamide combination. 16 Tumor location was not specifically assessed in this meta-analysis.
← all excerpts
Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience.
1
—
—